This is an open-label, single-center, non-randomized study to assess the efficacy of Clostridium Butyricum Miyairi on the motor and non-motor symptoms of Parkinson's disease
Eligibility
Sex
ALL
Min age
20 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Male or female over 20 years old, diagnosed with Parkinson's disease.
Exclusion Criteria:
* People with Parkinson's disease Dementia, or Lactose Intolerance
Primary outcome measure(s)
MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3 — 0, 3, 12, 15, 24 months Part 3 of this scale assesses motor performance in 33 items. Each item is scored on a scale of 0 (normal) to 4 (severe), with a total score range of 0 to 132, and higher scores mean the patient's situation is worse.
Hamilton Depression Rating Scale (HAM-D) — 0, 3, 12, 15, 24 months This scale assesses non-motor symptoms in 17 items, the total scale value is 50 (Scores 0 to 7 mean normal, 8 to 13 mean mild depression, 14 to 18 mean moderate depression, 19 to 22 mean severe depression, and ≥23 mean very severe depression).
Hamilton Anxiety Scale (HAM-A) — 0, 3, 12, 15, 24 months This scale assesses non-motor symptoms in 14 items. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where ≤17 indicates mild anxiety severity, 18-24 indicate mild to moderate anxiety severity, 25-30 indicate moderate to severe anxiety severity, \>30 indicate severe anxiety.
Trial sites (1)
Facility
City
Region
Status
Kaohsiung Medical Univeristy Hospital
Kaohsiung City
Taiwan
Recruiting
More Kaohsiung Medical University Chung-Ho Memorial Hospital trials in Taiwan
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
